UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV

PloS one, 2022-02, Vol.17 (2), p.e0262917-e0262917

2022

Link zum Volltext

Verfügbarkeit prüfen

Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models

Scientific reports, 2022-11, Vol.12 (1), p.18575-18575, Article 18575

2022

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients

PloS one, 2017-07, Vol.12 (7), p.e0181890-e0181890

2017

Link zum Volltext

Verfügbarkeit prüfen

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

AIDS (London), 2014-10, Vol.28 (16), p.2407-2415

2014

Link zum Volltext

Verfügbarkeit prüfen

TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype

World journal of gastroenterology : WJG, 2016-10, Vol.22 (38), p.8509-8518

2016

Link zum Volltext

Verfügbarkeit prüfen

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals

PloS one, 2022-02, Vol.17 (2), p.e0262917

2022

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity

Journal of acquired immune deficiency syndromes (1999), 2019-10, Vol.82 (2), p.175

2019

Link zum Volltext

Verfügbarkeit prüfen

Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy

Epidemiology and infection, 2020-01, Vol.148, p.e19-e19, Article e19

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy

European journal of epidemiology, 2012-08, Vol.27 (8), p.657-665

2012

Link zum Volltext

Verfügbarkeit prüfen

SAT-220-Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation

Journal of hepatology, 2019-04, Vol.70 (1), p.e726-e727

2019

Link zum Volltext

Verfügbarkeit prüfen

Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)–Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin

Clinical infectious diseases, 2016-02, Vol.62 (4), p.527-528

2016

Link zum Volltext

Verfügbarkeit prüfen

Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals

Journal of hepatology, 2017-08, Vol.67 (2), p.415-417

2017

Link zum Volltext

Verfügbarkeit prüfen

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir

Medicine (Baltimore), 2016-05, Vol.95 (22), p.e3780

2016

Link zum Volltext

Verfügbarkeit prüfen

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

International journal of infectious diseases, 2023-04, Vol.129, p.266-273

2023

Link zum Volltext

Verfügbarkeit prüfen

Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)–Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin: Table 1

Clinical infectious diseases, 2015-10, p.civ902

2015

Link zum Volltext

Verfügbarkeit prüfen

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients

BMC infectious diseases, 2017-01, Vol.17 (1), p.43-43, Article 43

2017

Link zum Volltext

Verfügbarkeit prüfen

High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting

Journal of viral hepatitis, 2021-03, Vol.28 (3), p.558-568

2021

Link zum Volltext

Verfügbarkeit prüfen

Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies

International journal of cancer, 2012-06, Vol.130 (12), p.2990-2996

2012

Link zum Volltext

Verfügbarkeit prüfen

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

AIDS (London), 2010-03, Vol.24 (6), p.924-928

2010

Link zum Volltext

Verfügbarkeit prüfen

Immortal time bias: authors' reply

AIDS (London), 2015-04, Vol.29 (7), p.860-861

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical, Virologic, and Immunologic Outcomes in Lymphoma Survivors and in Cancer-Free, HIV-1―Infected Patients: A Matched Cohort Study

Cancer, 2013-08, Vol.119 (15), p.2710-2719

2013

Link zum Volltext

Verfügbarkeit prüfen

Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply

AIDS (London), 2015-04, Vol.29 (7), p.857-859

2015

Link zum Volltext

Verfügbarkeit prüfen

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

Journal of antimicrobial chemotherapy, 2012-01, Vol.67 (1), p.213-217

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(55)

Sprache

Englisch
(55)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV

Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals

Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity

Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy

Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy

SAT-220-Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation

Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)–Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin

Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)–Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin: Table 1

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients

Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy

FRI401 - Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy

High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting

Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Immortal time bias: authors' reply

Clinical, Virologic, and Immunologic Outcomes in Lymphoma Survivors and in Cancer-Free, HIV-1―Infected Patients: A Matched Cohort Study

Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

Suchergebnisse filtern